Market PotentialThe updated American College of Rheumatology guidelines recommend Lupkynis as part of a first-line triple immunosuppressive regimen, suggesting improved adoption.
Regulatory ApprovalJapanese Health Authorities have approved Lupkynis for the treatment of lupus nephritis, which will trigger a $10M milestone payment and up to 20% royalties on future sales in Japan.
Revenue GrowthLupkynis product revenue increased 36% year over year, indicating strong growth.